Polymeric & Hybrid Nanoparticle Platform for CAR Delivery

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

While conventional viral vectors remain the gold standard for CAR gene delivery, their clinical translation is heavily bottlenecked by strict cargo size limits, high manufacturing costs, and inherent insertional mutagenesis risks. To address these critical hurdles, we offer a cutting-edge Polymeric & Hybrid Nanoparticle Platform designed specifically for next-generation, non-viral CAR engineering. Our comprehensive, end-to-end service encompasses everything from precision core self-assembly and lipid shell encapsulation to bespoke cell-specific surface functionalization. By leveraging this versatile matrix, we provide clients with highly stable, biocompatible, and multiplexed delivery formulations that drastically accelerate both ex vivo and direct in vivo immunotherapy pipelines.

Introduction

Polymeric and hybrid nanoparticles are a versatile class of nanocarriers distinguished by their tunable physicochemical properties, biocompatibility, and capacity for multifunctional surface engineering. These platforms exhibit exceptional advantages, including controlled drug release kinetics, enhanced stability in biological fluids, and the ability to co-deliver synergistic therapeutic agents, all while enabling active targeting via ligand decoration. These nanoparticles have emerged as transformative tools, offering innovative solutions for ex vivo CAR gene delivery, in vivo CAR T-cell generation, and spatiotemporal modulation of CAR immune cell activity, thereby addressing critical limitations such as off-tumor toxicity, manufacturing complexity, and immunosuppressive tumor microenvironments.

Fig.1 Applications of polymer-lipid hybrid nanoparticles. (OA Literature) Fig.1 Polymer–lipid hybrid nanoparticles and their applications. ¹

Our Service

Our Polymeric & Hybrid Nanoparticle Platforms offer an advanced, non-viral solution for CAR delivery. Combining polymer stability with lipid biocompatibility, this platform ensures highly efficient, targeted delivery of genetic cargo to immune cells. We provide clients with customizable, scalable formulation services that bypass viral limitations, significantly accelerating preclinical development of next-generation in vivo and ex vivo cell therapies.

What We Can Offer

We offer state-of-the-art polymeric and hybrid nanoparticle platforms engineered with active targeting, enhanced endosomal escape, stimuli-responsive release, and combination delivery capabilities to achieve precise, highly efficient, and synergistic in vivo or ex vivo CAR gene delivery for advanced immunotherapy.

Featured services of polymeric & hybrid nanoparticle platforms for CAR delivery at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

CAR plasmid DNA or mRNA (pDNA or mRNA).
Monoclonal antibodies targeting T cell or NK cell surface antigens.
Immune effector cells for genetically engineering.

Key Steps:

Workflow of polymeric & hybrid nanoparticle platforms for CAR delivery at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

CAR immune cell formulations.
Functional validation data.

Key Advantages

Enhanced Structural Stability and Nucleic Acid Protection: Our platform leverages a polymer core to condense genetic payloads via electrostatic interactions, coupled with an outer lipid bilayer that provides a robust shield against nuclease degradation and ensures superior colloidal stability in circulation.
High Endosomal Escape Efficiency: By incorporating smart cationic polymers that trigger the "proton sponge effect" within acidic endosomal environments, the platform facilitates rapid endosomal rupture, leading to highly efficient cytoplasmic release of CAR genes.
Customizable Surface Modification for Active Target Homing: The versatile lipid shell allows for precise chemical conjugation of cell-specific monoclonal antibodies, enabling active targeting of T/NK cells and unlocking the potential for direct, streamlined in vivo CAR reprogramming.

FAQ

Q1: How does your platform guarantee the conjugational integrity and efficiency of targeting antibodies on the nanoparticle surface?

A1: We utilize bioorthogonal chemistry to covalently tether ligands to the distal termini of surface-grafted PEG chains. This precise anchoring approach allows us to fine-tune ligand density while preventing premature shedding in complex biological fluids, thereby securing robust, target-specific cell homing in vivo.

Q2: Can this hybrid platform accommodate large-sized DNA payloads or CRISPR-Cas9 genome editing machinery?

A2: Yes, overcoming the strict packaging constraints of viral systems represents a primary strength of our electrostatic self-assembly design. The platform easily encapsulates massive payloads, ranging from large CAR plasmids to CRISPR-Cas9 ribonucleoproteins or multiplexed mRNA/sgRNA combinations, enabling seamless, single-vector gene knockout and CAR integration.

Why Choose Us?

Accelerate your immunotherapy pipeline with our advanced lipid-polymer hybrid nanoparticle platform. By integrating superior structural protection with targeted endosomal escape and flexible, virus-free multiplex loading, we deliver high-efficiency, low-toxicity CAR gene delivery engineered for precise ex vivo and in vivo clinical translation.

Customer Reviews

"Utilizing this hybrid nanoparticle platform has transformed our in vivo CAR delivery workflow. The customizable surface modification allowed highly specific T cell targeting within complex murine models. We achieved exceptional transduction efficiency without the safety liabilities of viral vectors." Dr. K* D*.

"Traditional cationic polymers often trigger severe cytotoxicity, but this platform's hybrid lipid-polymer architecture solves that bottleneck. In our primary T-cell assays, cell viability consistently exceeded 90%, with negligible inflammatory cytokine release. This exceptional biocompatibility expands our therapeutic window, giving us immense confidence in the safety profile of our non-viral CAR development program." Prof. S* C*.

How to contact us?

Elevate your non-viral vector development by collaborating with our cell therapy specialists. From refining ex vivo cellular engineering protocols to establishing novel in vivo clinical modalities, we engineer customizable nanomedicine matrices tailored to your precise specifications. Reach out to our technical team now to secure project pricing and fast-track your next-generation oncological pipeline.

Reference

Mohanty, Ayeskanta et al. "Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy." Molecules (Basel, Switzerland) vol. 25,19 4377. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/molecules25194377.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.